Literature DB >> 35135104

Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.

Kalyan Banda1, Elizabeth M Swisher1, David Wu1, Colin C Pritchard1, V K Gadi1.   

Abstract

Entities:  

Year:  2018        PMID： 35135104     DOI： 10.1200/PO.17.00044

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  1 in total

1.  Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12.

Authors:  Dolores Gallardo-Rincón; Edgar Montes-Servín; Gabriela Alamilla-García; Elizabeth Montes-Servín; Antonio Bahena-González; Lucely Cetina-Pérez; Flavia Morales Vásquez; Claudia Cano-Blanco; Jaime Coronel-Martínez; Ernesto González-Ibarra; Raquel Espinosa-Romero; Rosa María Alvarez-Gómez; Abraham Pedroza-Torres; Denisse Castro-Eguiluz
Journal:  Front Genet       Date:  2022-06-06       Impact factor: 4.772
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.